Pioneering Lysosomal Ion Channel Modulators for Neurodegeneration
Developing highly brain-penetrant lysosomal ion channel modulators — including TRPML1 and TMEM175 agonists — to restore autophagy-lysosomal function in age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, and FTD, as well as rare genetic lysosomal disorders like Batten disease.
News
Restoring Lysosomal Function via Ion Channel Modulation
Why Lysosomal Ion Channels Matter
With aging, the autophagy-lysosomal pathway (ALP) progressively declines, leading to impaired protein turnover, organelle damage, and the accumulation of toxic aggregates — including alpha-synuclein, Aβ, p-tau tangles, TDP-43, and lipofuscin — seen across major neurodegenerative diseases. Lysosomal ion channels such as TRPML1, TMEM175, ATP12A2, and TPC2 function as key signaling sensors that regulate calcium homeostasis, membrane potential, and proton gradients required for ALP activation. By directly modulating these channels — the control nodes capable of reactivating and rejuvenating the aging ALP — we address the upstream biology driving neurodegeneration rather than chasing downstream consequences.
Our Pipeline: Synergistic Programs To Address Multiple Distinct Lysosomal/Autophagy Deficiencies
Leadership Team
Our management team has tremendous relevant experience and expertise in lysosomal biology, drug discovery and development.
President and CEO
SVP, Drug Development
SVP, Head of Research and Translational Sciences
Senior Director,
Discovery Research
Discovery Research



Board of Directors
Christoph M. Adams, PhD
Independent Board Member
Frank Yan, PhD
Member, 3E Bioventures
Adam Sun, MBA
Board Observer, Oceanpine Capital
Tina Xu, PhD
Member, Highlight Capital
Yongchang Qiu, PhD
Chair, Founder



